Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

A Case of Profound Weight Loss Secondary to use of Reboxetine

Neslim Güvendeger Doksat* and Mehmet Kerem Doksat

Department of Psychology, Beykent University, Istanbul, Turkey

*Corresponding Author:
Neslim Güvendeger Doksat
Department of Psychology
Beykent University, Istanbul, Turkey
Tel: 90-5335564035
Fax: 90-(212)2764302
E-mail: neslimdoksat@doksat.com

Received Date: May 01, 2014; Accepted Date: June 06, 2014; Published Date: June 13, 2014

Citation: Doksat NG and Doksat MK (2014) A Case of Profound Weight Loss Secondary to use of Reboxetine. J Child Adolesc Behav 2:142. doi:10.4172/2375-4494.1000142

Copyright: © 2014 Doksat NG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Reboxetine is a selective norepinephrine re-uptake inhibitor used in the treatment of depression. The studies testing the effects of reboxetine on body weight have demonstrated that reboxetine reduces body weight and reboxetine found to be superior to placebo in reducing antipsychotic-induced weight gain. To date there are only a few cases in the literature of reboxetine use in adults resulting in profound weight loss. We present an unusual case report of a patient who experienced a marked weight loss with reboxetine treatment, regained weight after its withdrawal and experienced marked weight loss after re-challenge with reboxetine.

Keywords

Top